Southeast Asia Market Entry Guide for Indian Herbal Ingredient Suppliers: Indonesia, Singapore, and Malaysia

Southeast Asia is the last structurally uncovered region in our nine-market framework, and it is also the most fragmented. Unlike the European Union or unlike Brazil and Mexico in Latin America, there is no single dominant regulatory model here. Three different philosophies operate side by side across a few hours of flight time: Indonesia’s positive-list registration system, Singapore’s post-market self-declaration model, and Malaysia’s full mandatory approval process. An Indian herbal ingredient supplier who understands one of these markets cannot assume the other two will work the same way.

This guide focuses on Indonesia, Singapore, and Malaysia as the three markets that justify dedicated regulatory treatment, based on market size, regulatory complexity, and current trade relevance to Indian exporters. Thailand, Vietnam, and the Philippines are covered briefly at the end. As with our other market-entry guides, the goal is an accurate compliance map, not legal advice; verify specifics directly with a regulatory consultant or customs broker before committing to pricing or shipment.

Indonesia: BPOM and the Largest Market in the Region

Indonesia is Southeast Asia’s largest economy and most populous country, with over 270 million people and a health supplement sector that has shifted from price-driven demand toward quality, safety, and credibility-focused buying, particularly among the country’s growing urban middle class. For an Indian exporter of botanical extracts, ashwagandha, turmeric, or moringa, Indonesia represents the single largest addressable buyer base in the region. It also carries the most regulatory friction.

The Two-Track Classification

The first and most consequential decision in the Indonesian market is which of two regulatory tracks a product falls under, both overseen by BPOM (Badan Pengawas Obat dan Makanan, Indonesia’s National Agency of Drug and Food Control):

• Health supplements, governed under BPOM Regulation No. 11 of 2020, covering products built from vitamins, minerals, amino acids, and other nutritional substances, with or without non-nutritional ingredients.
• Traditional medicine, governed under a separate framework (BPOM Regulation No. 32 of 2019, with significant updates under PerBPOM No. 10 of 2024), covering Jamu, standardized herbal medicines, and phytopharmaceuticals.

This fork matters because the two tracks carry different documentation requirements, different clinical evidence expectations, and different labeling rules. A turmeric extract marketed as a general wellness supplement and the same extract marketed with traditional-medicine framing can end up on two entirely different regulatory paths. Getting this classification wrong early is one of the most common and costly mistakes foreign brands make entering Indonesia, and it is worth resolving with a local regulatory consultant before finalizing product positioning, not after.

The Positive List and the Negative List

Once a product is classified as a health supplement, BPOM uses a dual-list system to govern ingredients. The Positive List, found in Annex VII of BPOM Regulation No. 32 of 2022 as amended by Regulation No. 15 of 2024, is a catalog of pre-approved vitamins, minerals, amino acids, and functional ingredients, each with a defined maximum daily intake. The Negative List, in Annex VIII of the same regulation, names substances that are strictly prohibited, including pharmaceutical compounds, controlled substances, and ingredients derived from protected plant or animal species under Indonesian conservation law.

Many common Indian botanical extracts will not appear explicitly on either list. In that case, BPOM requires a formal safety assessment before the ingredient can be approved for use in a health supplement. This is structurally similar to the European Union’s Novel Food gap-filling process covered in our EU market entry guide: an ingredient with no prior regulatory history in the destination market requires a dedicated assessment rather than automatic approval, and that assessment takes meaningfully longer than registering an already-listed ingredient.

The Local License Holder Requirement

A foreign manufacturer cannot register a product with BPOM directly. An Indonesian-registered entity, holding the relevant manufacturing or import certification, must act as the license holder and the official point of contact with BPOM throughout the registration process and afterward. This is a heavier structural requirement than anything in our Latin America or USA guides, and it means the practical first step for an Indian exporter targeting Indonesia is identifying and vetting a credible local partner, not preparing a product dossier.

Imported products additionally require a Border Import Certificate (SKI Border), a separate electronic application with its own document set and a defined processing window after submission.

Halal Certification: Moving From Optional to Mandatory

Indonesia’s halal certification regime, under the Halal Product Assurance Law, is in the middle of a phased transition from a voluntary market differentiator to a mandatory compliance requirement for nearly all products entering, circulating in, or traded within the country. Food, beverage, and cosmetic categories face an October 2026 deadline, with pharmaceutical categories following on a later phased timeline. For an Indian herbal ingredient supplier, this is not optional context: it is the single most time-sensitive compliance item in the Indonesian market right now, and it sits directly on top of the existing BPOM registration burden.

There is a meaningful mitigation worth knowing about: if a supplier’s product is already halal-certified by a certifying body recognized by Indonesia’s halal authority, it may be possible to register that existing certification rather than undergo a fully separate local audit. Given the deadline is approaching within months of this guide’s publication, any Indian supplier without an existing recognized halal certification should treat this as an immediate action item, not a future one.

Singapore: The Structural Opposite of Indonesia

If Indonesia represents the highest-friction entry point in this comparison, Singapore is close to the lowest, and the contrast is instructive precisely because the two countries sit a short flight apart.

Singapore’s Health Sciences Authority (HSA) explicitly defines health supplements to include substances derived from natural sources, including botanical materials in the form of extracts, isolates, and concentrates, putting Indian herbal extracts squarely within scope of the category. But unlike Indonesia, health supplements in Singapore are not subject to pre-market approval or licensing at all. There is no positive list filing, no mandatory registration number, and no local license holder requirement of the kind Indonesia demands.

A Post-Market, Self-Declared Model

Singapore instead operates a post-market regulatory model. Responsibility for ensuring a product is safe, accurately labeled, and compliant rests with the “dealer,” a term covering importers, manufacturers, wholesale distributors, and sellers. Companies may voluntarily notify HSA of products they supply, but this is optional rather than required. HSA’s role is primarily reactive: post-market surveillance, random testing, and enforcement action if problems surface, rather than pre-market evaluation of every product before it reaches shelves.

This does not mean the category is lightly regulated in practice. Ingredients are still governed by a negative-list logic: substances controlled under the Poisons Act, the Misuse of Drugs Act, and the ASEAN Guiding Principles for the Negative List of Substances for Health Supplements are prohibited, as are ingredients tied to endangered species protections without the appropriate CITES import permit. The compliance burden in Singapore is concentrated almost entirely in labeling and claims discipline rather than in a pre-market dossier.

Claims Are Where the Real Risk Sits

Health supplements in Singapore may carry general health claims and functional health claims, both staying within HSA’s defined boundaries. The moment a claim implies treatment, prevention, or cure of a specific disease, the product risks reclassification into medicinal product territory, which brings the full pre-market evaluation the supplement category was designed to avoid. For an Indian exporter, this means label and marketing copy review is more valuable in Singapore than ingredient-level pre-clearance, the inverse of the Indonesian priority order.

Singapore’s domestic market is small relative to Indonesia’s, but its reputational weight is real: because HSA is widely respected as a rigorous regulator, products built to its labeling and claims standards often have an easier path expanding into other Southeast Asian markets afterward, making Singapore a reasonable first regional foothold even with a smaller direct buyer base.

A local importer must still hold a valid food import license through Singapore’s import system, so Singapore is not zero-friction. It is lower-friction in a specific and different way than Indonesia: the friction is logistical and claims-based rather than product-registration-based.

Malaysia: The Strictest of the Three

Malaysia’s National Pharmaceutical Regulatory Agency (NPRA), operating under the Ministry of Health, occupies the strictest position of the three anchor markets in this guide, and in some respects is stricter than either Indonesia or Singapore individually.

No Exempt Category

Where Singapore exempts health supplements from pre-market approval entirely, and Indonesia allows products on its Positive List a more direct registration path, Malaysia requires full registration through the Drug Control Authority (DCA) for essentially all natural and herbal products, with explicit category language naming Ayurvedic medicines, herbal teas, and dietary supplements as falling under this requirement. There is no notification-only or exempt tier comparable to Singapore’s model. Every registered product receives a MAL-prefixed registration number, which must appear on the product label alongside a mandatory hologram security label, and selling outside this system is treated as a compliance violation rather than a gray area.

The Food-Drug Interphase

Malaysia divides oversight between two separate bodies within its Ministry of Health: NPRA for medicinal and supplement products, and the Food Safety and Quality Division (FSQD) for general food. Many botanical products fall into what is locally known as the Food-Drug Interphase, an ambiguous zone where classification depends heavily on presentation and label claims, similar in structure to the health-supplement-versus-traditional-medicine fork in Indonesia above. When classification is unclear, a joint committee between the two agencies conducts a formal review to determine which agency leads. Resolving this question before finalizing labeling and marketing claims is far cheaper than discovering the answer after a rejected registration application.

Timeline and Local Registration Holder

Malaysia’s registration timelines are the longest of the three markets covered in depth in this guide. Standard drug evaluations can run up to 210 working days, with some health supplement applications following shorter tracks, though actual processing time depends heavily on submission completeness. As with Indonesia, a foreign company cannot apply directly: a local Product Registration Holder, a Malaysia-registered entity, must manage the application and maintain the registration once granted, which is typically valid for five years before renewal.

Health claims in Malaysia must be supported by scientific evidence and are restricted to health maintenance and promotion language, similar in spirit to Singapore’s claims discipline but enforced through a pre-market registered claims list rather than post-market review.

Comparing the Three Markets

The differences between Indonesia, Singapore, and Malaysia are not differences of degree on a single spectrum. Each reflects a genuinely different regulatory philosophy, and collapsing them into a single timeline-and-fee comparison would understate how differently each system actually works.

Factor	Indonesia (BPOM)	Singapore (HSA)	Malaysia (NPRA)
Underlying logic	Positive-list registration with formal assessment for unlisted ingredients	Post-market self-declaration, no pre-market approval	Mandatory full registration, no exempt category
Pre-market approval required	Yes	No	Yes
Local entity required	Yes, mandatory license holder	Local import license, not a product license holder	Yes, mandatory Product Registration Holder
Typical timeline	Multi-step registration plus SKI Border for imports	No registration timeline; compliance is ongoing	Up to 210 working days for standard evaluation
Where compliance risk concentrates	Ingredient list status and category classification	Labeling and health claims	Product classification (food vs. medicinal) and documentation completeness
Halal certification	Moving toward mandatory, October 2026 deadline for food/beverage	Not a comparable mandatory requirement	Halal certification common but not structured as comparably urgent deadline
Market size signal	Largest population and growing middle-class demand	Smaller domestic market, strong regional credibility role	Mid-sized market

Thailand, Vietnam, and the Philippines: Brief Notes

The remaining Southeast Asian markets did not receive dedicated deep-dive treatment in this guide, either because their regulatory documentation is less consolidated in English-language sources or because they do not yet present a sufficiently distinct story to justify the same depth as Indonesia, Singapore, and Malaysia, though all three remain commercially relevant. Thailand, regulated by the Thai FDA, generally follows a registration-based model for herbal and supplement products with its own documentation requirements distinct from both the Indonesian and Malaysian approaches. Vietnam, regulated by the Ministry of Health through its Vietnam Food Administration, represents one of the larger population and growth opportunities in the region, but consistently reliable English-language regulatory documentation for herbal categories specifically is thinner than for the three anchor markets, itself a signal that a Vietnam-based regulatory partner matters more here than in markets with more accessible public documentation. The Philippines, regulated by its national Food and Drug Administration, has an active and growing trade relationship with India; the two countries’ most recent Joint Working Group meeting in mid-2026 specifically discussed accelerating the review of the regional trade agreement covered below, alongside exploring a dedicated bilateral preferential trade agreement.

Trade Treatment: AITIGA and What It Actually Covers

Unlike several of the markets covered in our other market-entry guides, India’s preferential trade relationship with Southeast Asia is not a new or pending arrangement. The ASEAN-India Trade in Goods Agreement, commonly called AITIGA, was signed in 2009 and has been in force since January 1, 2010, covering trade in goods between India and all ten ASEAN member states, including Indonesia, Singapore, Malaysia, Thailand, Vietnam, and the Philippines. This is sixteen years of operating history, not a recently concluded or signed-but-pending deal of the kind flagged in our EU, Japan, ANZ, and Latin America guides.

That said, AITIGA’s coverage is narrower than several of India’s more recent trade agreements. India committed to eliminating tariffs on roughly 75 to 78 percent of its tariff lines under the agreement, a notably lower ambition than agreements like the India-UAE CEPA or the more recently concluded India-EU FTA. Both sides maintain sensitive lists and exclusion lists for specific categories, and the agreement explicitly carved out unique tariff schedules for a small set of India’s “special products,” including black tea and pepper.

What This Means for Botanical and Herbal Ingredient Exports Specifically

Based on the publicly documented sensitive and exclusion lists across Indonesia, Singapore, and Malaysia, raw botanical and herbal ingredient categories do not appear to be singled out for exclusion the way certain agricultural products, automotive parts, and base metals are. Singapore in particular maintains close to zero tariffs on most goods regardless of AITIGA, making the agreement largely a formalization of an already-open market rather than a new concession.

The more consistent and better-documented barrier across all three anchor markets is not tariff treatment. It is non-tariff: sanitary and phytosanitary measures, certification requirements, and the product-registration friction detailed in the Indonesia and Malaysia sections above. Indian agricultural exports more broadly, including spices, have historically faced more friction from certification and documentation requirements than from customs duty itself. For an Indian herbal ingredient exporter, the registration regime in each destination market is where the real cost of market entry sits, not the AITIGA tariff schedule.

A Live and Unresolved Process Worth Tracking

AITIGA is currently the subject of a substantial review and upgrade process. ASEAN and India agreed in 2023 to undertake the first comprehensive review since the agreement entered force, originally targeting completion by 2025. As of this guide’s publication in mid-2026, the review remains in active negotiation, with a recent round of talks held in Jakarta in March 2026 and both sides aiming for substantial conclusion sometime in 2026 or 2027. The outcome could change tariff-line coverage, rules of origin requirements, and non-tariff barrier provisions in ways not yet public. Given the review is active and unresolved, any Indian supplier finalizing a significant Southeast Asian export commitment should verify the current state of AITIGA negotiations and confirm specific HS code tariff treatment with a customs broker before finalizing pricing.

Getting Started

Southeast Asia rewards suppliers who treat its three largest markets as three separate regulatory projects rather than one regional strategy. Singapore is the fastest and lowest-friction entry point and a reasonable place to establish initial regional credibility. Indonesia offers the largest addressable market but demands a serious local partnership and, increasingly, halal certification readiness. Malaysia sits in between on market size but currently runs the strictest and slowest registration process of the three, with no shortcut available for herbal or traditional products.

For Indian herbal ingredient suppliers already exporting to other markets covered in this series, the underlying product documentation, GMP certification, and traceability practices built for those markets transfer substantially into Southeast Asia. What does not transfer automatically is the registration pathway itself, which has to be built fresh for each of these three markets given how differently each one is structured.